Literature DB >> 26459887

Antiviral activity of doxycycline against vesicular stomatitis virus in vitro.

Zhuan-Chang Wu1, Xin Wang2, Jian-Chao Wei1, Bei-Bei Li1, Dong-Hua Shao1, Yu-Ming Li1, Ke Liu1, Yuan-Yuan Shi1, Bin Zhou3, Ya-Feng Qiu1, Zhi-Yong Ma4.   

Abstract

Doxycycline (Dox) is a tetracycline derivative with broad-spectrum antimicrobial activities that is used as an effector substance in inducible gene-expression systems. We investigated the antiviral activity of Dox against vesicular stomatitis virus (VSV) infection in cultured H1299 cells. Dox at concentrations of 1.0-2.0 μg ml(-1) significantly inhibited VSV replication and the VSV-induced cytopathic effect in dose-dependent manners, suggesting that Dox may have broader activity in inhibiting viral replication, in addition to its well-defined bacteriostatic activity. Dox exerted its antiviral effect at the early-mid stage of VSV infection, suggesting that it did not interfere with VSV infectivity, adsorption, or entry into target cells. These results indicate that Dox can inhibit VSV infection and may therefore have potential applications for the treatment of viral infections. © FEMS 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antiviral activity; doxycycline; vesicular stomatitis virus

Mesh:

Substances:

Year:  2015        PMID: 26459887     DOI: 10.1093/femsle/fnv195

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  16 in total

1.  The NF-κB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses.

Authors:  Crystal A Mendoza; Satoko Yamaoka; Yoshimi Tsuda; Keita Matsuno; Carla M Weisend; Hideki Ebihara
Journal:  Antiviral Res       Date:  2020-12-06       Impact factor: 5.970

Review 2.  Repurposing of antibiotics for clinical management of COVID-19: a narrative review.

Authors:  Abdourahamane Yacouba; Ahmed Olowo-Okere; Ismaeel Yunusa
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-05-21       Impact factor: 3.944

3.  Inhibition of Rabies Virus by 1,2,3,4,6-Penta-O-galloyl-β-d-Glucose Involves mTOR-Dependent Autophagy.

Authors:  Zhongzhong Tu; Wenjie Gong; Yan Zhang; Ye Feng; Yan Liu; Changchun Tu
Journal:  Viruses       Date:  2018-04-17       Impact factor: 5.818

4.  Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.

Authors:  Chiara Bonzano; Davide Borroni; Andrea Lancia; Elisabetta Bonzano
Journal:  Front Med (Lausanne)       Date:  2020-05-08

Review 5.  The Use of Antimalarial Drugs against Viral Infection.

Authors:  Sarah D'Alessandro; Diletta Scaccabarozzi; Lucia Signorini; Federica Perego; Denise P Ilboudo; Pasquale Ferrante; Serena Delbue
Journal:  Microorganisms       Date:  2020-01-08

Review 6.  Tetracycline and viruses: a possible treatment for COVID-19?

Authors:  Jesús A Mosquera-Sulbaran; Hugo Hernández-Fonseca
Journal:  Arch Virol       Date:  2020-11-02       Impact factor: 2.574

7.  A novel plan to deal with SARS-CoV-2 and COVID-19 disease.

Authors:  Raphael B Stricker; Melissa C Fesler
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

8.  p53 promotes ZDHHC1-mediated IFITM3 palmitoylation to inhibit Japanese encephalitis virus replication.

Authors:  Xin Wang; Zhuanchang Wu; Yuming Li; Yifan Yang; Changguang Xiao; Xiqian Liu; Xiao Xiang; Jianchao Wei; Donghua Shao; Ke Liu; Xufang Deng; Jiaqiang Wu; Yafeng Qiu; Beibei Li; Zhiyong Ma
Journal:  PLoS Pathog       Date:  2020-10-27       Impact factor: 6.823

9.  A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction.

Authors:  Y-H Taguchi; Turki Turki
Journal:  PLoS One       Date:  2020-09-11       Impact factor: 3.240

10.  In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.

Authors:  Mathieu Gendrot; Julien Andreani; Priscilla Jardot; Sébastien Hutter; Océane Delandre; Manon Boxberger; Joel Mosnier; Marion Le Bideau; Isabelle Duflot; Isabelle Fonta; Clara Rolland; Hervé Bogreau; Bernard La Scola; Bruno Pradines
Journal:  Molecules       Date:  2020-10-31       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.